LEP and Behcet disease: Firstly, we evaluate whether the distribution of leptin and adiponectin and their ratio differ between patients with SMI (SCZ or BD) compared to healthy controls (HC), and between subgroups of AP medication, and secondly if this difference is mitigated by BMI.